Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
British Journal of Cancer
|
July 1, 1996
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report
D C Linch, B Vaughan Hudson, B W Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
R M Rudd, N H Gower, S G Spiro, et al.
Leukemia
|
August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K D Boyd, F M Ross, L Chiecchio, et al.
Blood Cancer Journal
|
December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J R Jones, D A Cairns, W M Gregory, et al.
Leukemia
|
June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V Shah, A L Sherborne, B A Walker, et al.
Blood Cancer Journal
|
June 17, 2017
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
M Went, A Sud, P J Law, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
British Journal of Cancer
|
July 1, 1996
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report
D C Linch, B Vaughan Hudson, B W Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group
R M Rudd, N H Gower, S G Spiro, et al.
Leukemia
|
August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K D Boyd, F M Ross, L Chiecchio, et al.
Blood Cancer Journal
|
December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J R Jones, D A Cairns, W M Gregory, et al.
Leukemia
|
June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V Shah, A L Sherborne, B A Walker, et al.
Blood Cancer Journal
|
June 17, 2017
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
M Went, A Sud, P J Law, et al.
Page
of 9